Article

Topical steroid a good choice for long-term allergy treatment

Molecular structure allows inactivation, reducing risk of intraocular side effects

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Subscribe Now!
Related Videos
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
Related Content
Targeted therapies improve care for Demodex blepharitis and OSD
June 19th 2025

Targeted therapies improve care for Demodex blepharitis and OSD

3 Things You Should Know About the GA Pipeline
June 4th 2025

3 Things You Should Know About Interventional Glaucoma Comanagement

(Image credit: AdobeStock/peopleimages.com) Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS
June 18th 2025

Rethinking end points in AMD: the power of OCT imaging with Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS

Patient-Centered Treatment Strategies in the Management of nAMD and DME
May 30th 2025

Patient-Centered Treatment Strategies in the Management of nAMD and DME

Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada
June 18th 2025

Johnson & Johnson launches TECNIS Odyssey IOL in Europe, Middle East, and Canada

Eyestem completes phase 1 study of Eyecyte-RPE in patients with geographic atrophy
June 18th 2025

Eyestem completes phase 1 study of Eyecyte-RPE in patients with geographic atrophy

© 2025 MJH Life Sciences

All rights reserved.